|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jim Huang, PhD, explains how a niche CDMO, which has specialized technologies in complex injectable development and adopts GMP practice with a “laboratory setting,” will have greater flexibility regarding changes, timing, and cost for successful manufacture of complex injectables in early phase development of therapeutic drugs.
|
|
|
In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2020 product approvals.
|
|
|
Aldo Romano and Emily Moran, MBA, discuss how the life science industry must bring technology solutions to the table while at the same time securing the capacity to develop and manufacture groundbreaking cures so patients and society can tap the benefits of cell and gene therapies.
|
|
|
Michael Snape, PhD, says when identifying promising therapeutic targets for any disease or condition, including developmental disorders such as Fragile X syndrome, PMS, CDM1, and Rett syndrome, it is critical researchers work to understand the mechanism of disease and disease pathways as well as the unmet need and patient experience.
|
|
|
|
|
|
|
|
|

Singota Solutions is a contract development and manufacturing organization (CDMO) focused on getting products to patients faster by being agile, accountable, and transparent. Founded in 2006, and headquartered in Bloomington, Indiana, Singota provides responsive, quality driven outsourcing services. Singota can fill parenterals into ready-to-use vials, syringes, or cartridges utilizing our gloveless, robotic, aseptic filling workcell for pre-clinical, clinical, and small commercial therapies. Our manufacturing process ensures freedom from in-process human intervention by not only removing the impact of operators from the initial aseptic environment but also by removing operator variability from the filling process. Click here for more.
|
|
|
|
|
|
 |
|
Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….
|
|
 |
|
Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….
|
|
 |
|
Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has collaborated with AARDEX Group, an expert in digital….
|
|
 |
|
LEXEO Therapeutics recently announced it has licensed worldwide intellectual property rights and preclinical data from Adverum Biotechnologies to its….
|
|
 |
|
WuXi AppTec recently announced that it has completed the acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene….
|
|
|
|
|
Upcoming eNewsletter Features:
March 17 – Analytical Instruments
March 24 – Parenteral Contract Manufacturing
|
|
|
|
|
|
|
|